Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 5/20 | 0.50 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216424 | 0.88 | SYK (0.61) | SYKATMPPARACTRB1CTSK | |
| SCHEMBL6936043 | 0.88 | SYK (0.61) | SYKATMPPARACTRB1CTSK | |
| SCHEMBL6621110 | 0.86 | SYK (0.59) | SYKATMPPARACTSKMAPT | |
| SCHEMBL7594328 | 0.85 | SYK (0.64) | SYKATMPPARACTRB1CTSK | |
| SCHEMBL2402783 | 0.84 | CTRB1 (0.58) | SYKATMCTRB1CTSKCTSS | |
| SCHEMBL21340066 | 0.84 | SYK (0.66) | SYKPPARACTSKCTSSCTSL | |
| SCHEMBL2137438 | 0.84 | SYK (0.62) | SYKATMPPARACTSKCTSS | |
| SCHEMBL2137432 | 0.84 | SYK (0.62) | SYKATMPPARACTSKCTSS | |
| SCHEMBL11127997 | 0.84 | SYK (0.66) | SYKPPARACTSKCTSSCTSL | |
| SCHEMBL13688643 | 0.84 | SYK (0.66) | SYKPPARACTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-2024333-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007125331-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | PKD2, PKD1, AADAT | SYK 2554/4885ATM 431/4885PPARA 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.